Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors
- 1 February 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (2) , 509
- https://doi.org/10.1200/jco.1999.17.2.509
Abstract
PURPOSE: This phase II study was designed to determine the toxicity and activity of single-agent gemcitabine in heavily pretreated patients with germ cell tumors. PATIENTS AND METHODS: From March 1...Keywords
This publication has 26 references indexed in Scilit:
- Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.Journal of Clinical Oncology, 1998
- Testicular Germ-Cell CancerNew England Journal of Medicine, 1997
- Activity of gemcitabine in platinum-resistant ovarian germ cell cancerEuropean Journal Of Cancer, 1996
- Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancerAnnals of Oncology, 1996
- Paclitaxel in extensively pretreated nonseminomatous germ cell tumorsUrologic Oncology: Seminars and Original Investigations, 1995
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patientsCancer Treatment Reviews, 1983
- VP16-213 as a single agent in advanced testicular tumorsPublished by Elsevier ,1980
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977
- Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumorsCancer, 1974